A pair of former MIT researchers think they've unlocked the next generation of mRNA using synbio 'logic circuits'

Strand Therapeutics emerged from stealth Wednesday with a $52 million Series A to advance its pipeline of programmable, self amplifying mRNA therapies initially targeted at solid tumor immuno-oncology, the biotech said.